Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[A Case of Metastatic Colon Cancer Dramatically Affected by Anti-EGFR Antibody Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Nov 2016

Yagi Ryoma, Shimada Yoshifumi, Miura Kohei, Tajima Yosuke, Okamura Takuma, Nakano Masato, Ichikawa Hiroshi, Nagahashi Masayuki, Sakata Jun, Kobayashi Takashi, Kameyama Hitoshi, Wakai Toshifumi, Nogami Hitoshi, Maruyama Satoshi, Takii Yasumasa

Abstract excerpt

RAS mutation is an established predictive biomarker of resistance to anti-epidermal growth factor receptor(EGFR)therapy in metastatic colorectal cancer. In addition, previous studies identified mutations in ERBB2, FGFR1, PDGFRA, BRAF, MAP2K1, PTEN, and PIK3CA as potential mechanisms of resistance to anti-EGFR therapy. Testing for these mutations might be necessary to determine eligibility for anti-EGFR therapy in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to FGFR1 gene

Share to Lung Neoplasms

Share to Mutation

Share to Rectal Neoplasms

Share to Treatment Outcome

Source

Identifiers

PMID: 28133136

Genes

EGFR
BRAF
ERBB2
FGFR1
PDGFRA
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[A Case of Metastatic Colon Cancer Dramatically Affected by Anti-EGFR Antibody Therapy].PMID 28133136Read ↗

[Prediction of EGFR blockade responses in metastatic colorectal carcinoma].Semantic proximity Read ↗

A multiple metastatic colon cancer patient with extra-long survival and acquired BRAF mutation: case report and literature reviewSemantic proximity Read ↗

[Anti-EGFR antibody therapy for colorectal cancer].Semantic proximity Read ↗

[Biomarkers of Anti-EGFR Antibodies in the Treatment of Metastatic Colorectal Cancer].Semantic proximity Read ↗

A Critical Review of Second-Generation Anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer.Semantic proximity Read ↗

[Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer].Semantic proximity Read ↗

[Targeted therapies for metastatic colorectal cancer].Semantic proximity Read ↗

[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].Semantic proximity Read ↗

[Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].Semantic proximity Read ↗

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patientsSemantic proximity Read ↗

[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].Semantic proximity Read ↗

Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.